

OncoTherapy Science, Inc.

October 1, 2021

Poster presentation of OTSA101 research for cervical cancer  
at the 80<sup>th</sup> Annual Meeting of the Japanese Cancer Association

OncoTherapy Science, Inc. (President & CEO: Jae-Hyun Park; hereinafter, “OncoTherapy”) today announces that the study results of OTSA101 for cervical cancer were presented as a poster presentation at the 80<sup>th</sup> Annual Meeting of the Japanese Cancer Association.

In this research, the expression of Frizzled homologue 10 (FZD10) in human cervical cancer and the anti-tumor effect of OTSA101 in cervical cancer mouse model were investigated. In the expression analysis, high expression of FZD10 was found in 91% of cases. Furthermore, the strong tumor suppressive effect of yttrium90-conjugated anti-FZD10 antibody (OTSA101) was observed in cervical cancer xenograft model without severe toxicity. These suggest that therapeutic potential of OTSA101 as a new treatment option in cervical cancer.

OTSA101 is a human chimera anti-FZD10 antibody, and the safety and tumor accumulation after OTSA101 administration were confirmed by the investigator-initiated phase I study which was conducted in France. Currently, phase I clinical trial of OTSA101 conjugating radioisotope for synovial sarcoma has been initiated in Japan.